PRPO
Precipio, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$26.62
+1.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.5M | 24.0M | 16.0M | 15.2M | 9.4M |
| Cost of Revenue | 15.5M | 13.3M | 8.4M | 9.2M | 6.9M |
| Gross Profit | 12.0M | 10.7M | 7.6M | 6.0M | 2.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | 2.3M | 2.7M | 2.7M |
| SG&A Expense | 4.5M | — | 11.8M | 13.6M | 15.3M |
| General & Admin Expense | 789.0K | — | 11.7M | 13.5M | 15.2M |
| Selling & Marketing Expense | — | — | 100.0K | 100.0K | 100.0K |
| Other Expenses | 9.0M | 11.9M | (2.3M) | (2.7M) | (2.7M) |
| Total Operating Expenses | 13.5M | 11.9M | 11.8M | 13.6M | 15.3M |
| Cost and Expenses | 29.0M | 25.3M | 20.2M | 22.8M | 22.2M |
| Operating Income (EBIT) | (1.5M) | (1.2M) | (4.2M) | (7.6M) | (12.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | (24.0K) | 73.0K | 74.0K | 18.0K | 12.0K |
| Net Interest Income | 24.0K | (73.0K) | (74.0K) | (18.0K) | (12.0K) |
| Other Non-Op Income/Expense | 331.0K | 839.0K | (74.0K) | 1.8M | 619.0K |
| Non-Operating Income (excl Interest) | (307.0K) | (912.0K) | — | (1.8M) | (631.0K) |
| EBT (Pre-Tax Income) | (1.2M) | (363.0K) | (4.3M) | (5.9M) | (12.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (1.2M) | (363.0K) | (4.3M) | (5.9M) | (12.2M) |
| Earnings from Cont. Ops | (1.2M) | (363.0K) | (4.3M) | (5.9M) | (12.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (1.2M) | (363.0K) | (4.3M) | (5.9M) | (12.2M) |
| Per Share | |||||
| Basic EPS | ($0.65) | ($0.23) | ($2.93) | ($4.51) | ($10.73) |
| Diluted EPS | ($0.65) | ($0.23) | ($2.93) | ($4.51) | ($10.73) |
| Revenue Per Share | $15.36 | $14.98 | $10.89 | $11.71 | $8.27 |
| Shares | |||||
| Basic Shares Outstanding | 1.8M | 1.6M | 1.5M | 1.3M | 1.1M |
| Diluted Shares Outstanding | 1.8M | 1.6M | 1.5M | 1.3M | 1.1M |
| Profitability Metrics | |||||
| EBITDA | 246.0K | 1.5M | (2.7M) | (4.5M) | (10.6M) |
| D&A | 1.5M | 1.8M | 1.5M | 1.3M | 1.5M |
| EBIT | (1.2M) | (290.0K) | (4.2M) | (5.8M) | (12.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026